Sign in

Private company

Achilles Therapeutics plc

British biological products company based in Birmingham, active since 20202

In its 2024 annual report (Form 20-F) the company says: “The Company is a public limited company originally incorporated pursuant to the laws of England and Wales in November 2020 as a private limited company named Achilles TX Limited, with nominal assets and liabilities, for the purposes of becoming the ultimate holding company for Achilles Therapeutics UK Limited (formerly Achilles Therapeutics Limited).”5

Last updated Oct 21, 2026.

Overview

-$69.7MNet income, fiscal 20233
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersBirmingham, United Kingdom2
  • Incorporated inUnited Kingdom4
  • Business address245 Hammersmith Road, London, X0 W6 8Pw4
  • Filer categoryNon-accelerated filer, Emerging growth company4
  • Legal formPublic Limited Company2
  • LEI984500FDESEB1BE52A762
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address20 Colmore Circus Queensway, B4 6AT Birmingham, United Kingdom2
  • Registered withCompanies House, 130274602

See how the biggest companies compare on our leaderboards

Achilles Therapeutics plc (formerly Achilles TX Limited) and subsidiaries, or the Company, is a biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors. The Company is focused on advancing immuno-oncology therapeutics by exploiting its pioneering work in the field of tumor evolution and clonal neoantigens.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-48.9%Return on equity3
-$49.5MFree cash flow3

Financial statements

Operating income673-$75.3M in 2023+446% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$13.8M-$13.8M20192020: -$33.7M-$33.7M2020+145%2021: -$64.2M-$64.2M2021+90%2022: -$78.4M-$78.4M2022+22%2023: -$75.3M-$75.3M2023−4%
Net income673-$69.7M in 2023+398% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$14.0M-$14.0M20192020: -$33.2M-$33.2M2020+137%2021: -$61.1M-$61.1M2021+84%2022: -$71.2M-$71.2M2022+16%2023: -$69.7M-$69.7M2023−2%
Fiscal year201820192020202120222023
Research and development$9.1M6$22.6M7$42.2M3$57.3M3$58.2M3
Operating expenses$64.2M3$78.4M3$75.3M3
Operating income-$13.8M6-$33.7M7-$64.2M3-$78.4M3-$75.3M3
Income before tax-$61.1M3-$71.1M3-$69.2M3
Income tax$3.0K7$37.0K3$111.0K3$491.0K3
Net income-$14.0M6-$33.2M7-$61.1M3-$71.2M3-$69.7M3
Earnings per share-$31.147-$2.133-$1.823-$1.743
Earnings per share (diluted)-$31.147-$2.133-$1.823-$1.743
Shares (weighted, basic)28.7M shares339.1M shares340.0M shares3
Shares (weighted, diluted)28.7M shares339.1M shares340.0M shares3

Compare Achilles Therapeutics plc with another company

Corporate structure

Achilles Therapeutics plc sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Achilles Therapeutics plc

  • Achilles Therapeutics plc Birmingham, United Kingdom
    • ACHILLES THERAPEUTICS UK LIMITED Subsidiary · 100% · Altrincham, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Achilles Therapeutics plc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$22.1M3 Dec 31, 2023$20.3M3 Dec 31, 2022+9.1%
Accumulated depreciation$12.9M3 Dec 31, 2023$7.9M3 Dec 31, 2022+64.4%
Property and equipment, net$9.2M3 Dec 31, 2023$12.4M3 Dec 31, 2022−26.0%
Operating-lease assets (leased space)$4.4M3 Dec 31, 2023$8.1M3 Dec 31, 2022−45.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$131.5M3 Dec 31, 2023$173.3M3 Dec 31, 2022−24.1%

Former names

  • Achilles Therapeutics LtdNov 27, 2020 to Feb 3, 20214

Timeline

  1. Nov 18, 2020Founded Achilles Therapeutics plc is founded2

Filings

77 filings to the SEC since October 2021: 3 annual reports, 18 large holders, 56 other. The latest 20:

  1. Mar 21, 202515-12G EDGAR
  2. Mar 20, 20256-K EDGAR
  3. Mar 19, 2025S-8 POS S-8 POS (REG NUMBER 333-278501) EDGAR
  4. Mar 19, 2025S-8 POS S-8 POS (REG NUMBER 333-270344) EDGAR
  5. Mar 19, 2025S-8 POS S-8 POS (REG NUMBER 333-263220) EDGAR
  6. Mar 19, 2025S-8 POS S-8 POS (REG NUMBER 333-255063) EDGAR
  7. Mar 11, 2025EFFECT EDGAR
  8. Mar 11, 2025POS AM EDGAR
  9. Mar 11, 202525 EDGAR
  10. Mar 3, 2025144 EDGAR
  11. Mar 3, 2025144 EDGAR
  12. Feb 28, 20256-K EDGAR
  13. Feb 18, 2025144 EDGAR
  14. Feb 13, 2025SCHEDULE 13G/A EDGAR
  15. Feb 11, 2025144 EDGAR
  16. Feb 7, 2025144 EDGAR
  17. Feb 6, 2025144 EDGAR
  18. Feb 6, 2025144 EDGAR
  19. Feb 6, 2025144 EDGAR
  20. Feb 6, 2025144 EDGAR

The 77 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Achilles Therapeutics plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAchilles Therapeutics plc1
  • CIK0001830749
  • Filer statusNon-accelerated filer<br>emerging growth company1
  • Incorporated inUnited Kingdom1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address245 Hammersmith Road, London, X0 W6 8PW1
  • Phone44 (0)20 8154 46001
  • Shares outstanding41,082,948 as of Dec 31, 20233
  • On EDGAR sinceNov 27, 20201
  • Filings107 in all: 6-K (32), 144 (14), SC 13G/A (8), SC 13G (7), CORRESP (6), S-8 (4), S-8 POS (4), UPLOAD (4)1
    All 26 form types

    20-F (3), EFFECT (3), F-1/A (3), SC 13D/A (3), DRS/A (2), SEC STAFF LETTER (2), 15-12G (1), 25 (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRSLTR (1), F-1 (1), F-3 (1), POS AM (1), SC 13D (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Apr 4, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15